We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

5 hedge funds and large institutions have $403K invested in Hepion Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more capital invested

Capital invested by funds: $368K → $403K (+$35K)

17% less funds holding

Funds holding: 6 → 5 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
+$24.8K
2
Osaic Holdings
Osaic Holdings
Arizona
+$1.91K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$128K
2
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management
Wisconsin
-$12K
3
Morgan Stanley
Morgan Stanley
New York
-$1.91K
4
PFS
Prospera Financial Services
Texas
-$1.91K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$173K – – –
PFS
2
Prospera Financial Services
Texas
$97K -$1.91K -1 -3%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$93K – – –
Squarepoint
4
Squarepoint
New York
$37K +$24.8K +13 New
Osaic Holdings
5
Osaic Holdings
Arizona
$3K +$1.91K +1 New
SM
6
Sabby Management
Florida
– -$128K -73 Closed
Northwestern Mutual Wealth Management
7
Northwestern Mutual Wealth Management
Wisconsin
– -$12K -7 Closed
Morgan Stanley
8
Morgan Stanley
New York
– -$1.91K -1 Closed

HEPA Hedge Fund Activity: Q2 2020 in Review

5 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2020, worth a combined $403K — up 9.5% from $368K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of HEPA and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest buyer was Squarepoint, opening a new position worth an estimated $24.8K. The largest seller was Sabby Management, exiting entirely with an estimated $128K sold.

  • 5 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2020, down from 6 in Q1 2020.
  • Funds reported $403K of Hepion Pharmaceuticals stock for Q2 2020, up 9.5% quarter-over-quarter.
  • 2 funds opened new Hepion Pharmaceuticals positions in Q2 2020 and 3 closed out, a net change of -1 holder.
  • The largest Hepion Pharmaceuticals buyer in Q2 2020 was Squarepoint, an estimated $24.8K added.
  • The largest Hepion Pharmaceuticals seller in Q2 2020 was Sabby Management, an estimated $128K sold.

Based on aggregated 13F filings for Q2 2020.